Citius Pharmaceuticals (NASDAQ: CTXR) has transitioned from a development-stage biotechnology company to a commercial-stage entity with the launch of LYMPHIR (denileukin diftitox-cxdl), an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma (CTCL). The company reported that LYMPHIR generated $5.6 million in net product revenue during the first six months of fiscal 2026, with gross margins of approximately 80%. This revenue came from four months of commercial sales following the December 2025 launch through Citius Oncology (NASDAQ: CTOR).
The commercial progress of LYMPHIR is a significant milestone for Citius, as it provides the company with a revenue-generating asset in the oncology market. Payer coverage has reached nearly 100% of covered commercial lives, and 83% of targeted accounts have achieved formulary inclusion or are under active review as of May 2026. Additionally, Citius announced an initial shipment of LYMPHIR to Europe in April 2026, marking an expansion beyond the U.S. market.
Beyond its approved indication, LYMPHIR is being explored in combination with other therapies for additional oncology indications. Investigator-initiated studies have evaluated LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic cancers, and prior to CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma. Positive topline results from both Phase 1 studies were reported in fiscal 2026, suggesting potential label expansion opportunities.
Citius’ late-stage pipeline includes Mino-Lok, an antibiotic lock solution designed to salvage central venous catheters in patients with catheter-related bloodstream infections (CRBSIs) and central line-associated bloodstream infections (CLABSIs). These infections are particularly serious in cancer and hemodialysis patients who depend on central venous catheters for treatment. Mino-Lok met the primary and secondary endpoints in its pivotal Phase 3 trial, and there are currently no FDA-approved therapies specifically indicated to salvage infected central venous catheters. The therapy has received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA, and Citius holds worldwide rights through a license from The University of Texas MD Anderson Cancer Center. The company has received FDA guidance outlining a pathway to support a future New Drug Application submission, and investor materials estimate worldwide sales potential of approximately $1.8 billion.
Another key pipeline asset is Halo-Lido (CITI-002), a proprietary topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. Approximately 10 million people in the U.S. report hemorrhoid symptoms annually, yet there are currently no FDA-approved prescription products specifically for this indication. If approved, Halo-Lido could become the first prescription product for hemorrhoids in the U.S., creating a significant commercial opportunity. The company completed a Phase 2b study in 2023 and has met with the FDA to discuss next steps.
Citius is also developing a stem cell platform based on induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including lung injury associated with sepsis. In a proof-of-concept sheep model, interim results showed improvements in oxygenation, systemic shock, pulmonary vascular injury, and bacterial clearance compared with controls. Additional studies with larger sample sizes are warranted, and data will inform future human clinical trials.
The company’s strategy centers on assets that address significant unmet medical needs and offer differentiated commercial opportunities. With LYMPHIR generating revenue and multiple clinical-stage programs advancing, Citius is positioned for multiple potential catalysts. The leadership team, including CEO Leonard Mazur and Executive Vice Chairman Myron Holubiak, brings extensive pharmaceutical development and commercialization experience. As Citius continues to engage with the FDA on Mino-Lok and Halo-Lido, and expand LYMPHIR’s reach, the company is progressing toward becoming a diversified critical-care and oncology player.
